Bulletin
Investor Alert

Tilray Inc. Cl 2

NAS: TLRY

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Mar 5, 2021, 7:59 p.m.

/zigman2/quotes/209129655/composite

$

21.98

Change

+0.35 +1.62%

Volume

Volume 179,843

Quotes are delayed by 20 min

/zigman2/quotes/209129655/composite

Previous close

$ 22.65

$ 21.63

Change

-1.02 -4.50%

Day low

Day high

$18.23

$23.22

Open

52 week low

52 week high

$2.43

$67.00

Open

Company Description

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extract...

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment sales consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment sales consist of hemp seed, hemp foods, board spectrum hemp extract containing CBD which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Valuation

Price to Sales Ratio

4.95

Price to Book Ratio

3.50

Enterprise Value to Sales

5.67

Total Debt to Enterprise Value

0.29

Efficiency

Revenue/Employee

204,351.00

Income Per Employee

-263,178.00

Receivables Turnover

5.00

Total Asset Turnover

0.23

Liquidity

Current Ratio

1.91

Quick Ratio

1.40

Cash Ratio

1.05

Profitability

Gross Margin

5.45

Operating Margin

-60.49

Pretax Margin

-128.61

Net Margin

-128.79

Return on Assets

-29.43

Return on Equity

-82.25

Return on Total Capital

-17.33

Return on Invested Capital

-37.10

Capital Structure

Total Debt to Total Equity

91.28

Total Debt to Total Capital

47.72

Total Debt to Total Assets

36.08

Long-Term Debt to Equity

90.10

Long-Term Debt to Total Capital

47.10

Officers and Executives

Name Age Officer Since Title
Mr. Brendan Kennedy 46 2018 President, Chief Executive Officer & Director
Mr. Jon Levin 50 2020 Chief Operating Officer
Mr. Michael Kruteck 57 2020 Chief Financial Officer
Dr. Joshua Eades - 2014 Chief Science Officer & Vice President
Mr. Andrew Pucher 36 2019 Chief Corporate Development Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/01/2021 Rebekah Dopp
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2021 Christine Thompson St. Clare
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
02/23/2021 Michael B. Shtender-Auerbach
Director
5,929   0
02/23/2021 Michael B. Shtender-Auerbach
Director
20,392   0
02/23/2021 Michael B. Shtender-Auerbach
Director
89,349   0
02/23/2021 Michael B. Shtender-Auerbach
Director
228,433   0
02/19/2021 Jon Levin
Chief Operating Officer
26,982   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2021 Michael Kruteck
Chief Financial Officer
23,476   Derivative/Non-derivative trans. at $0 per share. 0
02/19/2021 Jon Levin
Chief Operating Officer
56,738   Award at $0 per share. 0
02/19/2021 Michael Kruteck
Chief Financial Officer
53,191   Award at $0 per share. 0
01/25/2021 Brendan Kennedy
President and CEO; Director
57   0
01/25/2021 Brendan Kennedy
President and CEO; Director
3,371   0
01/25/2021 Michael B. Shtender-Auerbach
Director
202   0
01/25/2021 Michael B. Shtender-Auerbach
Director
517   0
01/25/2021 Michael B. Shtender-Auerbach
Director
116   0
01/01/2021 Brendan Kennedy
President and CEO; Director
12,777   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2021 Michael B. Shtender-Auerbach
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
12/18/2020 Michael B. Shtender-Auerbach
Director
3,595   0
12/18/2020 Michael B. Shtender-Auerbach
Director
13,895   0
12/18/2020 Andrew Pucher
Chief Corporate Dev Officer
7,497   Derivative/Non-derivative trans. at $0 per share. 0
12/18/2020 Michael B. Shtender-Auerbach
Director
61,289   0
12/18/2020 Michael B. Shtender-Auerbach
Director
156,693   0
12/18/2020 Andrew Pucher
Chief Corporate Dev Officer
3,303   Derivative/Non-derivative trans. at $0 per share. 0
12/16/2020 Christine Thompson St. Clare
Director
2,200   Disposition at $10 per share. 22,000
12/01/2020 Rebekah Dopp
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
12/01/2020 Christine Thompson St. Clare
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2020 Brendan Kennedy
President and CEO; Director
380,781   Derivative/Non-derivative trans. at $7.76 per share. 2,954,860
11/06/2020 Brendan Kennedy
President and CEO; Director
2,127   Disposition at $11.71 per share. 24,907
11/06/2020 Brendan Kennedy
President and CEO; Director
118,852   Disposition at $10.72 per share. 1,274,093
11/06/2020 Brendan Kennedy
President and CEO; Director
148,933   Disposition at $9.96 per share. 1,483,372
11/06/2020 Brendan Kennedy
President and CEO; Director
130,088   Disposition at $9 per share. 1,170,792
11/06/2020 Rebekah Dopp
Director
4,812   Disposition at $10 per share. 48,120
11/06/2020 Christine Thompson St. Clare
Director
4,400   Disposition at $10.05 per share. 44,220
/news/latest/company/us/tlry

MarketWatch News on TLRY

  1. Pot or Alcohol, Barron’s Has Never Favored Prohibition

    5:30 a.m. March 4, 2021

    - Kenneth G. Pringle

  2. Tilray stock price target raised to $21.00 from $9.20 at Stifel Nicolaus

    7:35 a.m. Feb. 23, 2021

    - Tomi Kilgore

  3. Marijuana Stock Tilray Is Rising. A Bull Is Stepping Aside.

    12:32 p.m. Feb. 18, 2021

    - Connor Smith

  4. Tilray stock price target raised to $32 from $18 at Alliance Global Partners

    8:43 a.m. Feb. 18, 2021

    - Tomi Kilgore

  5. Tilray downgraded to hold from buy at Benchmark

    6:29 a.m. Feb. 18, 2021

    - Tomi Kilgore

  6. Pot Stocks Are Flying High. Here Are 4 on Firm Footing.

    3:14 p.m. Feb. 13, 2021

    - Jack Hough

  7. Pot Stocks Are in the Spotlight. How to Tell Them Apart.

    1:10 p.m. Feb. 13, 2021

    - Connor Smith

  8. Loading more headlines...
/news/nonmarketwatch/company/us/tlry

Other News on TLRY

  1. Growth Bubble Bursts: All Good Things Come To An End

    8:00 a.m. March 6, 2021

    - Seeking Alpha

  2. Columbia Care: No Longer A Small Operator

    8:27 p.m. March 5, 2021

    - Seeking Alpha

  3. What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

    4:50 p.m. March 5, 2021

    - InvestorPlace.com

  4. CGC, TLRY, APHA and SNDL: Why Are Pot Stocks Down Today?

    2:09 p.m. March 5, 2021

    - InvestorPlace.com

  5. 7 Marijuana Stocks That Look Way Too Expensive Here

    5:01 a.m. March 5, 2021

    - InvestorPlace.com

  6. If You Like the Tilray Merger, Don’t Buy Tilray Stock

    3:21 p.m. March 4, 2021

    - InvestorPlace.com

  7. Cannabis ETFs are amongst today's top decliners

    12:35 p.m. March 4, 2021

    - Seeking Alpha

  8. Play a Game of ‘Pot Monopoly’ with Tilray Stock

    3:55 p.m. March 3, 2021

    - InvestorPlace.com

  9. Pro-Pot Politicians and a Massive Merger Should Catalyze Aphria Stock

    1:17 p.m. March 3, 2021

    - InvestorPlace.com

  10. Weedmaps: A Rare Combination Of Cannabis, Tech And SPAC

    12:47 p.m. March 3, 2021

    - Seeking Alpha

  11. Cannabis ETF (MSOS) On a High, Reaches $1B AUM Milestone

    11:10 a.m. March 3, 2021

    - Zacks.com

  12. What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

    4:18 p.m. March 2, 2021

    - InvestorPlace.com

  13. Cannabis Stocks: Why SNDL, APHA, TLRY and CGC Are Gaining Today

    1:19 p.m. March 2, 2021

    - InvestorPlace.com

  14. Ranking the Top 7 Marijuana Stocks From Best to Worst

    11:34 a.m. March 2, 2021

    - InvestorPlace.com

  15. Merger Arbitrage Mondays: SPAC IPOs Set A New Record

    12:42 p.m. March 1, 2021

    - Seeking Alpha

  16. Trulieve: Bullish Thesis Unchanged Despite Reefer Madness

    6:36 a.m. March 1, 2021

    - Seeking Alpha

  17. Recreational marijuana legalization is coming to Virginia

    2:24 a.m. March 1, 2021

    - Seeking Alpha

  18. Loading more headlines...

At a Glance

Tilray, Inc.

1100 Maughan Road

Nanaimo, British Columbia V9X IJ2

Phone

1 8448457291

Industry

Farming

Sector

Agriculture

Fiscal Year-end

12/2021

Revenue

$210.48M

Net Income

$-271.07M

2020 Sales Growth

26.1%

Employees

1,030

/news/pressrelease/company/us/tlry

Press Releases on TLRY

  1. The CBD Vape Oil Market is Already Seeing Soaring Demand

    8:00 a.m. March 3, 2021

    - Baystreet.ca

  2. Top Stocks To Buy Today? 4 Pot Stocks For Your List

    4:09 p.m. Feb. 24, 2021

    - StockMarket.com

  3. Regulatory Reform Could Mean Big Days for the CBD Industry

    9:27 a.m. Feb. 19, 2021

    - Financial News Media

  4. Regulatory Reform Could Mean Big Days for the CBD Industry

    9:25 a.m. Feb. 19, 2021

    - PR Newswire - PRF

  5. Global CBD Based Skin Care Market Could Exceed $3.45 Billion By 2026

    8:31 a.m. Feb. 18, 2021

    - Financial News Media

  6. Cannabis Reform Could Get a Major Boost in the U.S. this Year

    8:30 a.m. Feb. 18, 2021

    - Baystreet.ca

  7. Global CBD Based Skin Care Market Could Exceed $3.45 Billion By 2026

    8:30 a.m. Feb. 18, 2021

    - PR Newswire - PRF

  8. Cannabis Producer Tilray Reports First Quarterly Profit

    7:46 a.m. Feb. 18, 2021

    - Baystreet.ca

  9. Tilray, Inc. Reports 2020 Full Fiscal Year and Fourth Quarter Results

    4:16 p.m. Feb. 17, 2021

    - BusinessWire - BZX

  10. Tilray, Inc. to Host Earnings Call

    3:15 p.m. Feb. 17, 2021

    - ACCESSWIRE

  11. Loading more headlines...
Link to MarketWatch's Slice.